Overview

• The MHRA warns that GLP-1 receptor agonists such as Ozempic, Wegovy, Mounjaro, Saxenda and Victoza may reduce oral contraceptive effectiveness by causing nausea and vomiting that impair pill absorption.
• Alison Cave, MHRA safety director, stressed that these injections are approved for type 2 diabetes treatment and not authorized for elective weight loss without proper medical oversight.
• After more than 40 reports of unplanned pregnancies the regulator recommends women supplement oral contraceptives with barrier methods and maintain protection for up to two months after ending Ozempic or Wegovy.
• The MHRA advises against using these medications during conception, pregnancy or breastfeeding because there is insufficient evidence on their safety in those stages.
• Originally developed for diabetes, these injectables are increasingly prescribed off-label for weight loss often without consistent clinical supervision.